Drager expects 3% growth for 1995
This article was originally published in Clinica
German company Drager expects 3% growth in sales for 1995 from the DM 1,384 million ($971 million) in 1994. In constant currencies this would represent 6-7% growth. Group net profits are estimated to be slightly down on last year's DM 15.1 million. The company blames market conditions and the reorganisation of a US subsidiary. Despite price cuts in weaker currency markets, sales increased and earnings were stable.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.